Related Experiment Video
Updated: Mar 28, 2026
14:51
Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype
Published on: June 17, 2022
3.7K
Metformin Induces Cell Cycle Arrest and Apoptosis in Drug-Resistant Leukemia Cells
A Rodríguez-Lirio1, G Pérez-Yarza1, M R Fernández-Suárez1
1Department of Cell Biology and Histology, School of Medicine and Dentistry, University of the Basque Country, Leioa, 48940 Bizkaia, Spain.
Leukemia Research and Treatment
|December 22, 2015
Summary
Metformin shows antitumor effects in leukemia cells by inhibiting proliferation and inducing apoptosis. This antidiabetic drug modulates energy metabolism, offering new therapeutic insights for leukemia treatment.
Area of Science:
- Oncology
- Pharmacology
- Biochemistry
Background:
- Epidemiological studies suggest metformin possesses anticancer properties.
- Metformin, an antidiabetic drug, is being investigated for its potential in cancer therapy.
- Its effects on leukemia cells, including chemosensitization and chemoprevention, warrant further investigation.
Purpose of the Study:
- To investigate the antitumor activity of metformin against human leukemia cells.
- To elucidate the mechanisms underlying metformin's effects, including cell cycle arrest, apoptosis, and metabolic alterations.
- To explore the differential responses of metformin-sensitive and resistant leukemia cells.
Main Methods:
- Cell growth inhibition assays
- Apoptosis assays (caspase activation)
- Cell cycle analysis (S and G2/M phases)
- Mitochondrial membrane potential (Δψm) measurement
- Western blotting for cell cycle proteins (cyclins, cdc2)
- Analysis of protein kinase C epsilon (PKCε) and delta (PKCδ) expression and their impact on cellular metabolism.
Main Results:
- Metformin demonstrated varying antitumor activity across different leukemia cell lines.
- In sensitive cells, metformin induced S and G2/M phase arrest, downregulating specific cyclins and cdc2, without affecting cyclin E.
- In drug-resistant cells (10E1-CEM), metformin more potently inhibited proliferation and induced apoptosis via caspase 3/7 activation.
- Metformin decreased mitochondrial membrane potential (Δψm) in sensitive cells.
- Metformin altered the expression of PKCε and PKCδ, promoting a glycolytic state in sensitive cells, with the opposite effect in resistant cells.
Conclusions:
- Metformin exhibits significant antitumor potential in human leukemia cells.
- Its mechanism involves cell cycle arrest, apoptosis induction, and modulation of energy metabolism.
- Differential effects on PKCε/PKCδ expression suggest a role in metabolic reprogramming contributing to its antileukemic activity.
More Related Videos
Related Concept Videos
02:50Combination Therapies and Personalized Medicine
6.3K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
02:56Treatment Resistant Cancers
3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
02:57Targeted Cancer Therapies
9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.1K
02:34Inhibition of Cdk Activity
6.2K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.2K
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
929
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
929
02:38Mitogens and the Cell Cycle
8.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.4K